-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-507097-41-01
5
2025-03-20
Patients with limited-stage small cell lung cancer (LS-SCLC)
without
-
2024-514499-42-00
5
2025-03-12
Refractory Partial Onset Epilepsy
-
2024-513018-36-00
5
2025-03-06
Lung Diseases, Interstitial
-
2024-512536-29-00
4
2025-02-28
Amyotrophic Lateral Sclerosis (ALS)
-
2024-518224-74-01
4
2025-02-07
metastatic non-small-cell lung cancer
-
2024-511457-22-00
3
2025-01-30
Advanced Hematologic Malignancies
-
2024-514048-98-00
5
2025-01-30
Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cance
-
2024-511814-20-00
3
2024-12-10
Hemophilia
-
2023-507746-83-00
5
2024-11-27
Generalized Myasthenia Gravis
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2023-504358-36-00
5
2024-10-17
multiple sclerosis
-
2023-505606-42-00
5
2024-10-15
Head and Neck Squamous Cell Carcinoma (HNSCC)
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2023-510017-26-00
1
2024-10-02
Completely Resected Stage IIB, IIC, and III Melanoma
-
2022-502289-25-00
5
2024-08-28
Moderate to Severe Active Systemic Lupus Erythematosus
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-508441-41-00
6
2024-07-08
Bacteriemia producida por P. aeruginosa.
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2022-502050-14-00
5
2024-06-04
Crohn's disease
-
2023-503545-67-00
5
2024-04-30
Tourette's Disorder
-
2023-503221-19-00
4
2024-04-18
Advanced Non-Small Cell Lung Cancer
-
2023-503523-25-00
4
2024-02-29
Non-small cell lung cancer